Genomma Lab InternacionalB de CV (MEX:LABB) Operating Income : MXN4,063 Mil (TTM As of Mar. 2025)

View and export this data going back to 2008. Start your Free Trial

What is Genomma Lab InternacionalB de CV Operating Income?

Genomma Lab InternacionalB de CV's Operating Income for the three months ended in Mar. 2025 was MXN959 Mil. Its Operating Income for the trailing twelve months (TTM) ended in Mar. 2025 was MXN4,063 Mil.

Operating Margin % is calculated as Operating Income divided by its Revenue. Genomma Lab InternacionalB de CV's Operating Income for the three months ended in Mar. 2025 was MXN959 Mil. Genomma Lab InternacionalB de CV's Revenue for the three months ended in Mar. 2025 was MXN4,406 Mil. Therefore, Genomma Lab InternacionalB de CV's Operating Margin % for the quarter that ended in Mar. 2025 was 21.77%.

Good Sign:

Genomma Lab Internacional SAB de CV operating margin is expanding. Margin expansion is usually a good sign.

Genomma Lab InternacionalB de CV's 5-Year average Growth Rate for Operating Margin % was 1.60% per year.

Operating Income or EBIT is linked to Return on Capital for both regular definition and Joel Greenblatt's definition. Genomma Lab InternacionalB de CV's annualized ROC % for the quarter that ended in Mar. 2025 was 14.83%. Genomma Lab InternacionalB de CV's annualized ROC (Joel Greenblatt) % for the quarter that ended in Mar. 2025 was 45.35%.

Genomma Lab InternacionalB de CV Operating Income Historical Data

The historical data trend for Genomma Lab InternacionalB de CV's Operating Income can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Genomma Lab InternacionalB de CV Operating Income Chart

Genomma Lab InternacionalB de CV Annual Data

Trend

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

Operating Income

Get a 7-Day Free Trial

2,933.83

2,996.85

3,303.01

3,201.58

3,905.43

Genomma Lab InternacionalB de CV Quarterly Data
	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24	Mar25
Operating Income	Get a 7-Day Free Trial															855.45	983.28	1,128.81	991.71	959.46

Genomma Lab InternacionalB de CV Operating Income Calculation

Operating Income, is the profit a company earned through operations. All expenses, including cash expenses such as cost of goods sold (COGS), research & development, wages, and non-cash expenses, such as depreciation, depletion and amortization, have been deducted from the sales.

Operating Income for the trailing twelve months (TTM) ended in Mar. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was MXN4,063 Mil.

Genomma Lab InternacionalB de CV (MEX:LABB) Operating Income Explanation

1. Operating Income or EBIT is linked to Return on Capital for both regular definition and Joel Greenblatt's definition.

Genomma Lab InternacionalB de CV's annualized ROC % for the quarter that ended in Mar. 2025 is calculated as:

	ROC % (Q: Mar. 2025 )
=	NOPAT	/	Average Invested Capital
=	Operating Income * ( 1 - Tax Rate % )	/	( (Invested Capital (Q: Dec. 2024 )	+	Invested Capital (Q: Mar. 2025 ))	/ count )
=	3837.848 * ( 1 - 28.87% )	/	( (17048.21	+	19768.447)	/ 2 )
=	2729.8612824	/	18408.3285
=	14.83 %

where

	Invested Capital		(Q: Dec. 2024 )
=	Total Assets	-	Accounts Payable & Accrued Expense	-	Excess Cash
=	Total Assets	-	Accounts Payable & Accrued Expense	-	( Cash, Cash Equivalents, Marketable Securities	-	max(0, Total Current Liabilities	-	Total Current Assets	+	Cash, Cash Equivalents, Marketable Securities	))
=	23017.803	-	3604.554	-	( 2365.039	-	max(0, 6538.418	-	12066.531	+	2365.039	))
=	17048.21

	Invested Capital		(Q: Mar. 2025 )
=	Total Assets	-	Accounts Payable & Accrued Expense	-	Excess Cash
=	Total Assets	-	Accounts Payable & Accrued Expense	-	( Cash, Cash Equivalents, Marketable Securities	-	max(0, Total Current Liabilities	-	Total Current Assets	+	Cash, Cash Equivalents, Marketable Securities	))
=	24080.376	-	2154.904	-	( 2157.025	-	max(0, 8392.563	-	13053.358	+	2157.025	))
=	19768.447

Note: The Operating Income data used here is four times the quarterly (Mar. 2025) data.

2. Joel Greenblatt's definition of Return on Capital:

Genomma Lab InternacionalB de CV's annualized ROC (Joel Greenblatt) % for the quarter that ended in Mar. 2025 is calculated as:

	ROC (Joel Greenblatt) %		(Q: Mar. 2025 )
=	EBIT	/	Average of (Net fixed Assets	+	Net Working Capital)
=	EBIT	/	Average of (Property, Plant and Equipment	+	Net Working Capital)
			Q: Dec. 2024		Q: Mar. 2025
=	EBIT	/	( ( (Property, Plant and Equipment + Net Working Capital)	+	(Property, Plant and Equipment + Net Working Capital) )	/	count )
=	3685.096	/	( ( (3558.571 + max(4373.033, 0))	+	(3653.478 + max(4667.853, 0)) )	/	2 )
=	3685.096	/	( ( 7931.604	+	8321.331 )	/	2 )
=	3685.096	/	8126.4675
=	45.35 %

where Working Capital is:

	Working Capital		(Q: Dec. 2024 )
=	(Accounts Receivable	+	Total Inventories	+	Other Current Assets)	-	(Accounts Payable & Accrued Expense	+	Defer. Rev.	+	Other Current Liabilities)
=	(4444.414	+	2176.087	+	2915.909)	-	(3604.554	+	0	+	1558.823)
=	4373.033

	Working Capital		(Q: Mar. 2025 )
=	(Accounts Receivable	+	Total Inventories	+	Other Current Assets)	-	(Accounts Payable & Accrued Expense	+	Defer. Rev.	+	Other Current Liabilities)
=	(5371.263	+	2229.596	+	2500.484)	-	(2154.904	+	0	+	3278.586)
=	4667.853

When net working capital is negative, 0 is used.

Note: The EBIT data used here is four times the quarterly (Mar. 2025) EBIT data.

3. Operating Income is also linked to Operating Margin %:

Genomma Lab InternacionalB de CV's Operating Margin % for the quarter that ended in Mar. 2025 is calculated as:

Operating Margin %	=	Operating Income (Q: Mar. 2025 )	/	Revenue (Q: Mar. 2025 )
	=	959.462	/	4406.326
	=	21.77 %

4. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Operating Income growth rate using Operating Income per share data.

Be Aware

Compared with a company's EBITDA margin, Operating Margin can be manipulated by adjusting the rate of depreciation, depletion and amortization (DDA).

If a company is facing competition, its Operating Margin may decline. Often the Operating Margin declines well before the company's revenue or even profit decline. Therefore, Operating Margin is a very important indicator of whether the company is facing problems.

For instance, by 2012, Nokia (NOK)'s problems were well known and its stock had lost more than 90% of its market value since 2007. But Nokia's Operating Margin had already been in decline since 2002, although its earnings per share were still rising. Investors who paid attention to Operating Margin would have avoided this huge loss. The same can be said for Research-in-Motion (RIMM).

Therefore, Operating Margin is a very important screening filter for GuruFocus. GuruFocus's Buffett-Munger screener requires that the profit margin is either consistent or expanding. The Model Portfolio of the Buffett-Munger screener has outperformed the market every year since inception in 2009.

Genomma Lab InternacionalB de CV Operating Income Related Terms

Thank you for viewing the detailed overview of Genomma Lab InternacionalB de CV's Operating Income provided by GuruFocus.com. Please click on the following links to see related term pages.

Genomma Lab InternacionalB de CV Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Genomma Lab Internacional SAB de CV (MEX:LABB) » Definitions » Operating Income

Comparable Companies

Traded in Other Exchanges

GNMLF:USA GEKA:Germany

Address

Avenida Antonio Dovali Jaime, Number 70, Tower C, Floor 2, Office A. Colonia Santa Fe, Del. Alvaro Obregon, Mexico, MEX, MEX, CP 01210

Website

https://www.genommalab.com

Genomma Lab Internacional SAB de CV is a specialty and generic drug manufacturer. The company's stated goal is to improve and preserve the health and well-being of people through innovative, safe, and effective products. Genomma operates a wide variety of brands to serve different consumer needs, including pregnancy, pain medication, and deodorant. The company considers merger and acquisition investment as a potential component of its operational growth strategy for expanding its research, development, manufacturing, and marketing capabilities.

Genomma Lab InternacionalB de CV Headlines

No Headlines